Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Arenas

Showing results (361-370 of 378) with videos related to

Pageof 38
Sort By:
Blood|March 25, 2020
Increased mTOR activation in idiopathic multicentric Castleman diseaseDaniel J Arenas, Katherine Floess, Dale Kobrin, et al.
The Science of the Total Environment|June 11, 2011
Small-scale and household methods to remove arsenic from water for drinking purposes in Latin AmericaMarta I Litter, María Teresa Alarcón-Herrera, María J Arenas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" ConditionsB Ruiz-Antorán, J M Pascasio, F Gea, et al.
Molecular Ecology|December 28, 2016
Self-fertilization, long-distance flash invasion and biogeography shape the population structure of Pseudosuccinea columella at the worldwide scaleM Lounnas, A C Correa, A A Vázquez, et al.
Science Advances|May 20, 2022
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancerAnna Adam-Artigues, Enrique J Arenas, Alex Martínez-Sabadell, et al.
Journal of Viral Hepatitis|October 15, 2014
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients ProgramS Bruno, S Bollani, A L Zignego, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Cancer Discovery|September 13, 2023
Early-Stage Breast Cancer Detection in Breast MilkCristina Saura, Carolina Ortiz, Judit Matito, et al.
Genome Medicine|August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsAndrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Pageof 38

Showing results (361-370 of 378) with videos related to

Sort By:
Pageof 38
Blood|March 25, 2020
Increased mTOR activation in idiopathic multicentric Castleman diseaseDaniel J Arenas, Katherine Floess, Dale Kobrin, et al.
The Science of the Total Environment|June 11, 2011
Small-scale and household methods to remove arsenic from water for drinking purposes in Latin AmericaMarta I Litter, María Teresa Alarcón-Herrera, María J Arenas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" ConditionsB Ruiz-Antorán, J M Pascasio, F Gea, et al.
Molecular Ecology|December 28, 2016
Self-fertilization, long-distance flash invasion and biogeography shape the population structure of Pseudosuccinea columella at the worldwide scaleM Lounnas, A C Correa, A A Vázquez, et al.
Science Advances|May 20, 2022
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancerAnna Adam-Artigues, Enrique J Arenas, Alex Martínez-Sabadell, et al.
Journal of Viral Hepatitis|October 15, 2014
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients ProgramS Bruno, S Bollani, A L Zignego, et al.
Blood Advances|August 26, 2021
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman diseaseSheila K Pierson, Sushila Shenoy, Ana B Oromendia, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Cancer Discovery|September 13, 2023
Early-Stage Breast Cancer Detection in Breast MilkCristina Saura, Carolina Ortiz, Judit Matito, et al.
Genome Medicine|August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsAndrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Pageof 38